نتائج البحث

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

• Authors : GORTEC (Head and Neck Oncology and Radiotherapy Group); Merck KGaA, Darmstadt, Germany

• Source: A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With

تفاصيل العنوان

Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants

• Authors : National Cancer Institute (NCI); Eben Rosenthal, Dept Chairperson Professor

• Source: Head and Neck Tumor Tissue Repository and Clinical Database

تفاصيل العنوان

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

• Authors : Kyunghee Burkitt, DO, PhD, Principal Investigator

• Source: Biomarker Driven Phase 1/1b Trial of Decitabine and Nivolumab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckSiegel RL, Miller

تفاصيل العنوان

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

• Authors : Trisha Wise-Draper, Principal Investigator

• Source: WOPPPR: Window of Opportunity Phase I and Phase II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous

تفاصيل العنوان

PDT For Induction Therapy For Head And Neck Cancer

• Authors : Coherus Oncology, Inc.; Thomas J. Roberts, MD, Principle Investigator

• Source: A Phase 2 Study of Toripalimab in Combination With Cisplatin and Docetaxel (PDT) for Induction Therapy in CPS-Positive Locally Advanced Head and Neck Squamous Cell

تفاصيل العنوان

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

• Source: A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic

تفاصيل العنوان

Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer (COMPORT)

• Authors : Clinical Trials Unit, Bern, Switzerland; Fond'action contre le cancer; University Hospital, Zürich ...

• Source: COMPORT: Compartmentalization in Postoperative Radiotherapy for Head and Neck Squamous Cell Carcinoma - A Phase II Clinical Trial

تفاصيل العنوان

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

• Authors : Merck Sharp & Dohme LLC; Loren Mell, MD, Director, Division of Clinical and Translational Research/ Department of Radiation Medicine

• Source: Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+

تفاصيل العنوان

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

• Authors : Eben Rosenthal, Barry and Amy Baker Professor and Chair

• Source: Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

تفاصيل العنوان

Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer (AACER)

• Source: Phase II Study Evaluating Radiotherapy-chemotherapy and Cetuximab in Patients With Histologically Proven Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx and With a Poor

تفاصيل العنوان